We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE (EMERALD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05001737
Recruitment Status : Recruiting
First Posted : August 12, 2021
Last Update Posted : January 4, 2023
Sponsor:
Information provided by (Responsible Party):
Swedish Orphan Biovitrum

Brief Summary:
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.

Condition or disease Intervention/treatment Phase
Macrophage Activation Syndrome Secondary Hemophagocytic Lymphohistiocytosis Still Disease Systemic Lupus Erythematosus SJIA AOSD MAS Drug: Emapalumab Phase 3

Detailed Description:

Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as per their background disease. The cohorts are defined as follows:

  • Cohort 1: MAS in the context of sJIA and AOSD.
  • Cohort 2: MAS in the context of pediatric and adult SLE.

The study has the objectives to investigate the efficacy, safety and tolerability, for 8 weeks, and PK and PD, QoL and immunogenicity in these 2 cohorts for up to 1 year after last dose of of emapalumab.

Macrophage Activation Syndrome (MAS) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) systemic Juvenile Idiopathic Arthritis (sJIA) Adult-onset Still's Disease (AOSD) Systemic Lupus Erythematosus (SLE)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: 2 cohorts
Masking: None (Open Label)
Masking Description: Open label
Primary Purpose: Treatment
Official Title: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous
Actual Study Start Date : December 15, 2021
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : January 2024


Arm Intervention/treatment
Experimental: Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)
MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
Drug: Emapalumab
Emapalumab iv infusion
Other Names:
  • NI-0501
  • emapalumab-lzsg
  • ATC code: L04AA39 (WHO)




Primary Outcome Measures :
  1. Proportion of subjects with complete response (CR) at Week 8 after first administration of emapalumab [ Time Frame: 8 weeks ]

    Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm.

    Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Clinical signs will be considered as resolved if VAS is below or equal to 1/10.

    And

    Normalization of laboratory parameters relevant to MAS, as follows:

    WBC above LLN platelet count above LLN LDH below 1.5 ULN ALT below 1.5 ULN AST below 1.5 ULN fibrinogen higher than 100 mg/dL ferritin levels decreased by at least 80 % from values at screening or baseline (whichever is higher) or below 2000 ng/ml, whichever is low



Secondary Outcome Measures :
  1. GCs tapering to a dose below 50% of prednisolone (PDN) equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS whichever occurs first [ Time Frame: At any time in the study, up to 1 year ]
    GC tapering as per investigator discretion

  2. GCs tapering to ≤1mg/kg/day of PDN equivalent at any time during the study. [ Time Frame: At any time in the study, up to 1 year ]
    GC tapering as per investigator discretion

  3. Time to achieve GCs tapering as defined above. [ Time Frame: At any time in the study, up to 1 year ]
    GC tapering as per investigator discretion

  4. Time to first Complete Remission [ Time Frame: At any time in the study, up to 1 year ]
    Time to CR

  5. Proportion of subjects with overall response as defined by CR or PR [ Time Frame: At any time in the study, up to 1 year ]
    Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm.

  6. Time to first overall response as defined by CR or PR [ Time Frame: At any time in the study, up to 1 year ]

    CR defined as below:

    Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm.


  7. MAS recurrence at anytime after achievement of CR [ Time Frame: At any time after CR, up to 1 year ]
    Time to MAS recurrence after CR

  8. Withdrawal from the study due to lack of response as per Investigator decision [ Time Frame: At any time in the study, up to 1 year ]
    Time to withdrawal

  9. Survival time [ Time Frame: At any time in the study, up to 1 year ]
    Time to Survival


Other Outcome Measures:
  1. Adverse Events (AEs) (serious and non-serious). [ Time Frame: At any time in the study, up to 1 year ]
    Incidence, severity, causality and outcomes of AEs

  2. Study interruption due to safety reasons [ Time Frame: At any time in the study, up to 1 year ]
    Number of subjects withdrawn due to safety reasons

  3. Laboratory parameters [ Time Frame: At any time in the study, up to 1 year ]
    Changes from baseline

  4. Patient reported outcomes : PedsQL™; [ Time Frame: Screening, Week 8, month 6 and 1 year ]
    Pediatric Quality of Life Inventory (PedsQL™; Generic Core Scales and Infant Scales, Acute versions)

  5. Patient reported outcomes: Patient/Parent Global Impression of Severity [ Time Frame: Screening, Week 8, month 6 and 1 year ]
    Health-related quality of life: Global Assessment: Patient/Parent Global Impression of Severity

  6. Patient reported outcomes: Clinician Global Impression of Severity [ Time Frame: Screening, Week 8, month 6 and 1 year ]
    Health-related quality of life: Global Assessment: Clinician Global Impression of Severity

  7. PK endpoints [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    Serum concentrations of emapalumab vs. time

  8. PK endpoints CEOI, [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    PK parameters by non-compartmental analysis: CEOI,

  9. PK endpoints: λz, [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    PK parameters by non-compartmental analysis: λz,

  10. PK endpoints: CL, [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    PK parameters by non-compartmental analysis: CL,

  11. PK endpoints: Vss, [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    PK parameters by non-compartmental analysis: Vss,

  12. PK endpoints: MRTlast and MRTinf [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    PK parameters by non-compartmental analysis: MRTlast and MRTinf, as applicable

  13. PD endpoints per cohort: free IFN-γ and total IFNγ [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    • Levels of circulating free IFN-γ at pre-dose, and total IFNγ (free IFN-γ+bound to emapalumab) after initiation of the study drug.

  14. PD endpoints per cohort: chemokines [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    Levels of the main IFN-γ-induced chemokines (CXCL9, CXCL10).

  15. PD endpoints per cohort: sCD25) [ Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year ]
    Levels of MAS markers (sCD25).

  16. Immunogenicity endpoints [ Time Frame: Treatment visit 1, week 8, 6 months, 1 year ]
    Occurrence of ADAs, Nab to emapalumab



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria Run-in phase in all cohorts

  1. Informed consent provided by the subject or by the subject s' legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as required by local law.
  2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of MAS.
  3. MAS defined as per the criteria defined below for each cohort and requiring treatment with GCs.

Interventional phase in all cohorts

  1. Informed consent provided by the subject or by the subject's legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as as required by local law.
  2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of active MAS.
  3. Subjects who have shown an inadequate response to high dose intravenous (i.v.) GCs administered for at least 3 days according to local standard clinical practice, including but not limited to pulses of 30 mg/kg PDN on 3 consecutive days. High i.v. GCs dose is recommended not to be lower than 2 mg/kg/ day PDN equivalent (or at least 60 mg/day in pediatric subjects of 30 kg or more, and at least 1g/day in adult MAS subjects). In case of rapid worsening of the subject's condition and/or laboratory parameters, as per Investigator judgment, inclusion may occur within less than 3 days from starting high dose GCs.
  4. Diagnosis of active MAS confirmed by the treating rheumatologist, having ascertained the followings:

    a. Febrile subjects presenting with ferritin > 684 ng/mL. b. and any 2 of: i. Platelet count ≤ 181 x109/L ii. AST-level > 48 U/L iii. Triglycerides > 156 mg/dL iv. Fibrinogen level ≤ 360 mg/dL

  5. Female subjects of child-bearing potential willing to use highly effective methods of contraception from study drug initiation to 6 months after the last dose of study drug.

    Specific inclusion criteria to Cohort 1 and Cohort 2

  6. Cohort 1:

    1. Confirmed sJIA diagnosis. For subjects presenting with MAS in the context of the onset of sJIA, high presumption of sJIA will suffice for eligibility.
    2. Confirmed diagnosis of AOSD as per Yamaguchi criteria.
  7. Cohort 2:

    1. Confirmed diagnosis of SLE as per SLICC'12 criteria.

Exclusion criteria

  1. Primary HLH documented by either the presence of a known causative genetic mutation or abnormal perforin expression and CD107a degranulation assay as described with primary hemophagocytic lymphohistiocytosis or by the presence of family history.
  2. Confirmed malignancy. Note: subjects with a suspected malignancy should have mononuclear cells typed by flow cytometry and/or tissue biopsy, as applicable, to rule out malignancy.
  3. Treatment with canakinumab, JAK inhibitors, TNF inhibitors and tocilizumab at the time of emapalumab initiation.
  4. Ongoing treatment with anakinra at a dose above 4 mg/kg at time of emapalumab initiation.
  5. Subjects treated with etoposide for MAS in the last 1 month.
  6. Clinically active mycobacteria (typical and atypical), Histoplasma Capsulatum, or Salmonella infections.
  7. Evidence of leishmania infections.
  8. Evidence of latent tuberculosis.
  9. History of hypersensitivity or allergy to any component of the study drug.
  10. Receipt of a Bacillus Calmette-Guerin (BCG) vaccine within 12 weeks prior to screening.
  11. Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screening.
  12. Pregnancy or lactating female subjects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05001737


Contacts
Layout table for location contacts
Contact: Adnan Mahmood, MD +46730983984 Adnan.Mahmood@sobi.com
Contact: Marc Messier, PhD Marc.Messier@sobi.com

Locations
Show Show 42 study locations
Sponsors and Collaborators
Swedish Orphan Biovitrum
Investigators
Layout table for investigator information
Study Chair: Radmila Kanceva, MD Swedish Orphan Biovitrum
Layout table for additonal information
Responsible Party: Swedish Orphan Biovitrum
ClinicalTrials.gov Identifier: NCT05001737    
Other Study ID Numbers: NI-0501-14
2021-001577-24 ( EudraCT Number )
First Posted: August 12, 2021    Key Record Dates
Last Update Posted: January 4, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphohistiocytosis, Hemophagocytic
Lupus Erythematosus, Systemic
Macrophage Activation Syndrome
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Histiocytosis, Non-Langerhans-Cell
Histiocytosis
Lymphatic Diseases
Lymphoproliferative Disorders
Immunoproliferative Disorders